Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival
- Conditions
- Disorder of Transplanted Kidney
- Registration Number
- NCT02017990
- Lead Sponsor
- Oslo University Hospital
- Brief Summary
This study will evaluate the association between n-3 polyunsaturated fatty acids and patient and graft survival. The association between other fatty acids and mortality and graft loss endpoints will also be evaluated.
- Detailed Description
This observational study focuses on the effects of marine n-3 polyunsaturated fatty acids (PUFAs) intake, measured as fatty acid levels in plasma phospholipids, and mortality and graft loss endpoints in renal transplant recipients. Data on morbidity, mortality and graft loss in The Norwegian Renal Registry is matched against data on fatty acid composition in a large renal transplantation cohort of approximately 2000 patients with a median follow up time of about 5 years. It is a follow up study, although retrospectively evaluated. It will evaluate the role of marine n-3 PUFAs as a prognostic marker in renal transplantation by investigating the association between the levels (weight percentage of total fatty acids) of marine n-3 PUFAs in plasma phospholipids and events, including mortality and graft loss.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2002
- Received a renal transplant. Signed informed consent.
- Under the age of 16 years.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality Up to 12 years. First patient recruited October 1999 and all remaining patients were censored at August 2012.
- Secondary Outcome Measures
Name Time Method Loss of function in the renal transplant. Up to 12 years. As for primary endpoint.
Trial Locations
- Locations (1)
Oslo University Hospital, Rikshospitalet
🇳🇴Oslo, * Oslo, Norway